52 Week Range
As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Aspen Pharmacare Sells Japanese Ops To Sandoz For Up To Eur 400 Mln
Aspen Pharmacare Says In Talks On Selling A Commercial Business In Asia Pacific Region
Aspen Says No Dividend Been Declared For Year
Aspen Pharmacare Holdings Limited is a South Africa-based supplier and manufacturer of branded and generic pharmaceutical products, as well as infant nutritional and consumer healthcare products. The Company's segments include International, South Africa, Asia Pacific and Sub-Saharan Africa (SSA). Its International business includes operating subsidiaries in Europe, Commonwealth of Independent States (CIS), Latin America, the Middle East and North Africa, Canada, as well as Mauritius-based Aspen Global Incorporated. The South African business provides branded, generic, over-the-counter, consumer health and infant nutritional products, which are supplied to pharmacies, retail pharmacy chains, hospitals, clinics, prescribing specialists, dispensing general practitioners, managed healthcare funders and retail stores across the private and public sectors in South Africa. Its business in Asia Pacific includes operations in Australasia, the Philippines, Taiwan and Japan.
Kuseni Douglas Dlamini
Independent Non-Executive Chairman of the Board
Stephen Bradley Saad
Group Chief Executive, Executive Director
Michael Guy Attridge
Deputy Group Chief Executive Officer, Finance Director, Executive Director
Group Finance Officer
Chief Executive Officer, Aspen Global Incorporated CEO
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Novartis <NOVN.S> is buying the Japanese generics unit of South Africa's Aspen Pharmacare <APNJ.J> in a deal worth up to 400 million euros (344.5 million pounds) to expand in the world's third-biggest drug market, the Swiss drugmaker said on Monday.
Aspen Pharmacare Holdings <APNJ.J> agreed to sell its Japanese operations to Novartis' Sandoz <NOVN.S> for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.
Aspen Pharmacare Holdings agreed to sell its Japanese operations to Novartis' Sandoz for up to 400 million euros ($440.80 million) through a unit as it looks to cut debt, the South African drugmaker said on Monday.
Novartis' Sandoz generic drug unit is buying Aspen's Japanese operations for an initial payment of 300 million euros ($330.60 million) to expand in the world's third-biggest generic medicines market, the Swiss drugmaker said on Monday.
* ASPEN PHARMACARE HOLDINGS LTD - PROPOSED DEAL FOR FOR A CASH CONSIDERATION OF UP TO EUR 400 MILLION
The U.S. Food and Drug Administration (FDA) has approved Aspen Pharmacare's hydroxyprogesterone caproate (HPC), which is used to prevent preterm birth in pregnant women, the South African drugmaker's CEO said on Thursday.
* Intends to restart heparin supply to third-parties (Adds details)
South African drugmaker Aspen Pharmacare Holdings said on Wednesday full-year normalised earnings fell by 7% and it would not pay a dividend this year.
Aspen Pharmacare Holdings Ltd <APNJ.J> said on Tuesday its debt as of June 30 had fallen below 40 billion rand ($2.63 billion) and that levels were safely below a covenant threshold, sending shares in the South African drugmaker up more than 9%.
British authorities said on Wednesday South Africa's Aspen Pharmacare Holdings Ltd <APNJ.J> has agreed to pay the National Health Service (NHS) 8 million pounds to resolve concerns related to overpayment for a treatment.
British authorities said on Wednesday South Africa's Aspen Pharmacare Holdings Ltd has agreed to pay the National Health Service (NHS) 8 million pounds ($9.65 million) to resolve competition concerns related to a company's treatment.
South African drugmaker Aspen Pharmacare said on Friday it had terminated talks with a potential partner in Europe, after announcing in March a strategic review of its European and domestic commercial pharmaceuticals businesses.
Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).
Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy Aspen's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).
South Africa's rand firmed on Friday, recovering from a nine-week low after sluggish U.S. employment data pushed the dollar lower and saw demand for emerging markets return.
* Debt levels still within creditor threshold (Adds historical debt, details)
Shares of South Africa-based drugmaker Aspen Pharmacare plunged nearly 40 percent on Friday, as rising debt worried investors.
Multinational drugmaker Aspen Pharmacare said it will split its South African Commercial Pharmaceuticals business into two divisions as it disposes of non-core assets to reduce its debt.
Shares in Aspen Pharmacare fell more than 8 percent on Friday, a day after the South African drugmaker said it had negotiated a temporary relaxation of its lending agreements and forecast little growth in full-year revenues.
Aspen Pharmacare has struck a deal with U.S. generics maker Mylan to distribute a portfolio of prescription and over-the-counter drugs in Australia and New Zealand.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.